Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 10, 2023

SELL
$8.08 - $17.33 $89,389 - $191,721
-11,063 Reduced 21.23%
41,042 $683,000
Q4 2022

Feb 09, 2023

BUY
$2.72 - $9.4 $141,725 - $489,787
52,105 New
52,105 $489,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $2.61B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Landscape Capital Management, L.L.C. Portfolio

Follow Landscape Capital Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Landscape Capital Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Landscape Capital Management, L.L.C. with notifications on news.